Copper Rock

Copper Rock Therapeutics was a preclinical-stage biotechnology company focused on developing novel therapies that modulate copper homeostasis to treat metabolic disorders and cancer. Founded on research from Johns Hopkins University, the company targeted copper metabolism pathways, specifically focusing on Wilson's disease and various oncological indications where copper plays a critical role in disease pathology. The company's approach utilized specific copper-binding molecules to regulate intracellular copper levels and restore normal physiological function. In January 2020, Copper Rock Therapeutics was acquired by Theonys, a biotechnology firm specializing in tRNA-based therapies and metabolic diseases. The acquisition allowed for the integration of Copper Rock's copper-modulating programs into a broader therapeutic platform.